John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intel
INTC
|
+$267M |
| 2 |
Amazon
AMZN
|
+$243M |
| 3 |
Applied Materials
AMAT
|
+$242M |
| 4 |
Airbnb
ABNB
|
+$221M |
| 5 |
Meta Platforms (Facebook)
META
|
+$213M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Micron Technology
MU
|
+$262M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$259M |
| 3 |
Wells Fargo
WFC
|
+$238M |
| 4 |
Broadcom
AVGO
|
+$233M |
| 5 |
Applovin
APP
|
+$225M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.95% |
| 2 | Healthcare | 13.56% |
| 3 | Financials | 11.46% |
| 4 | Consumer Discretionary | 9.22% |
| 5 | Industrials | 9.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2901
Caesarstone
CSTE
$118M
| $97.2K | ﹤0.01% |
22,879
-20,986
| -48% | -$92.3K |
|
2902
Genelux
GNLX
$123M
| $97.2K | ﹤0.01% |
41,177
-18,446
| -31% | -$49.1K |
|
2903
Arbutus Biopharma
ABUS
$1.03B
| $96.4K | ﹤0.01% |
29,486
-240
| -0.8% | -$883 |
|
|
OTLY
2904
Oatly Group
OTLY
$507M
| $95.7K | ﹤0.01% |
7,217
+5,316
| +280% | +$78.3K |
|
2905
Metagenomi Therapeutics
MGX
$45.7M
| $95.6K | ﹤0.01% |
26,471
-59,135
| -69% | -$143K |
|
2906
AEye
LIDR
$56.3M
| $94.9K | ﹤0.01% |
74,736
+61,437
| +462% | +$70.9K |
|
2907
Lloyds Banking Group
LYG
$87.6B
| $94K | ﹤0.01% |
34,572
| – | – |
|
2908
Celularity
CELU
$22.4M
| $93.4K | ﹤0.01% |
+44,914
| New | +$107K |
|
2909
Karyopharm Therapeutics
KPTI
$42.2M
| $93.2K | ﹤0.01% |
9,186
+3,457
| +60% | +$41.8K |
|
2910
American Battery Technology Co
ABAT
$327M
| $92.9K | ﹤0.01% |
37,750
+10,756
| +40% | +$12.1K |
|
2911
1-800-Flowers.com
FLWS
$249M
| $91.9K | ﹤0.01% |
11,249
| – | – |
|
2912
Liberty Latin America Class C
LILAK
$1.64B
| $90.7K | ﹤0.01% |
15,730
| – | – |
|
2913
Verrica Pharmaceuticals
VRCA
$83.7M
| $89.9K | ﹤0.01% |
12,844
+1,316
| +11% | +$14.5K |
|
2914
Cumberland Pharmaceuticals
CPIX
$117M
| $89.2K | ﹤0.01% |
37,649
+18,271
| +94% | +$26.9K |
|
|
INZY
2915
DELISTED
Inozyme Pharma
INZY
| $88.4K | ﹤0.01% |
+31,924
| New | +$121K |
|
2916
Acacia Research
ACTG
$440M
| $87.6K | ﹤0.01% |
20,175
-7,065
| -26% | -$32K |
|
2917
Arcos Dorados Holdings
ARCO
$1.7B
| $87.1K | ﹤0.01% |
11,965
-428,311
| -97% | -$3.67M |
|
2918
Evolv Technologies
EVLV
$951M
| $86.9K | ﹤0.01% |
+22,000
| New | +$77.2K |
|
2919
Atossa Therapeutics
ATOS
$26.3M
| $84.8K | ﹤0.01% |
5,989
-426
| -7% | -$8.32K |
|
2920
CareCloud
CCLD
$106M
| $84.5K | ﹤0.01% |
23,093
-11,048
| -32% | -$32.8K |
|
2921
Tenax Therapeutics
TENX
$69.2M
| $83.7K | ﹤0.01% |
+13,521
| New | +$65.6K |
|
2922
Compugen
CGEN
$245M
| $82.7K | ﹤0.01% |
54,042
-20,141
| -27% | -$32.8K |
|
2923
KALA BIO
KALA
$15.4M
| $82.4K | ﹤0.01% |
238
-42
| -15% | -$13.2K |
|
2924
TOP Financial Group
TOP
$2.01B
| $81.5K | ﹤0.01% |
+10,657
| New | +$91.9K |
|
2925
BioAtla
BCAB
$5.46M
| $79.9K | ﹤0.01% |
2,704
+1,235
| +84% | +$104K |
|
Similar funds
John Overdeck's Q4 2024 Portfolio in Review
As of Q4 2024, John Overdeck held 3,590 positions worth $45.9B, up 0.48% from $45.6B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
John Overdeck withdrew a net $1.69B in Q4 2024, closing 427 positions and reducing 1,388 holdings. Its most notable exit was iShares MSCI Emerging Markets ETF, an estimated $184M position sold in full.
By sector, the portfolio is most concentrated in Technology at 16% of assets, down from 18% a quarter earlier, followed by Healthcare and Financials.
Against the trend, John Overdeck opened a new position in Intel worth $237M.
- John Overdeck's largest Q4 2024 buy was Intel: 11,843,258 shares worth $237M.
- John Overdeck added most to Amazon in Q4 2024, an estimated $243M increase.
- John Overdeck's biggest Q4 2024 reduction was Micron Technology, cutting an estimated $262M.
- John Overdeck fully exited iShares MSCI Emerging Markets ETF in Q4 2024, selling an estimated $184M.
- John Overdeck's ten largest holdings make up 7.2% of its $45.9B portfolio in Q4 2024.
- John Overdeck opened 477 new positions and closed 427 in Q4 2024.
- John Overdeck's portfolio value rose 0.48% quarter-over-quarter to $45.9B.
Based on Two Sigma Investments's 13F filing for Q4 2024, filed 14 Feb 2025.